Furthermore, intratumor MLKL-mRNA delivery synergizes with immune-checkpoint blockades (ICBs), impedes lymphoma growth in mice, and improves anti-tumor activity in syngeneic mice with colon carcinoma and melanomas [298]. Here, MLKL is linked to melanoma.